European Journal of Medicinal Chemistry p. 1107 - 1117 (2017)
Update date:2022-07-30
Topics:
Yu, Lei
Huang, Minhao
Xu, Tianfeng
Tong, Linjiang
Yan, Xiao-e
Zhang, Zhang
Xu, Yong
Yun, Caihong
Xie, Hua
Ding, Ke
Lu, Xiaoyun
Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.
View MoreContact:+86-15850770348
Address:51 OF XIANGFANGCUN ROAD, Nanjing 210002, China
JiangXi Hong Run Chemical Co., Ltd
Contact:+86-0791-88521351
Address:XingHuo industrial zone in YongXiu county
FREEBARQUE DEVELOPMENT GROUP LIMITED
Contact:+86(0)10-5109 5335 or 5109 5345
Address:Room602,Block1-B,LINGDI OFFICE,NO.13 BEIYUAN ROAD
Changsha Yihai Chemical Technology Co.,ltd
Contact:0731- 85620465
Address:Room 23005, unit 2, the northern building of Xiangsong international building , NO.259 Shaoshan Road , Changsha , Hunan, China.(mainland)
Liaoyang hengye Chemical Co., Ltd.
Contact:86-419-5850866
Address:North Old Xiaoxiao Road,Yantai District, Dengta, Liaoyang, Liaoning, China
Doi:10.1271/bbb1961.42.809
(1978)Doi:10.1021/ja00479a037
(1978)Doi:10.1081/NCN-120022836
(2003)Doi:10.1016/0022-328X(85)88024-4
(1985)Doi:10.1021/je60079a005
(1978)Doi:10.1021/ja00524a047
(1980)